Description: BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
Home Page: www.brain-biotech.com
Darmstädter Strasse 34-36
Zwingenberg,
64673
Germany
Phone:
49 62 51 9331 0
Officers
| Name | Title |
|---|---|
| Mr. Adriaan Moelker | Chairman of the Management Board & CEO |
| Mr. Ulrich Putsch | Co-Founder |
| Mr. Michael Schneiders | CFO & Member of Management Board |
| Dr. Ute Dechert | VP of HR & Processes |
| Dr. Jurgen Eck | Consultant |
| Dr. Martin Langer | Exec. VP & Head of Bus. Devel. |
| Dr. Michael Krohn | Exec. VP and Head of R&D |
| Thomas Deichmann | Head of PR |
| Dr. Michael Waidelich | Head of Skin Care Bus. Unit |
| Mr. Robbert Michael Hoekstra | Head of Group Fin. |
Exchange: XETRA
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.8667 |
| Price-to-Sales TTM: | 2.8404 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 312 |